BMC GenomicsBioinformaticsPeer-reviewed journal article
Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios
Belén Otero-CarrascoiD, Esther Ugarte CarroiD, Lucia Prieto SantamaríaiD, Marina Díaz Uzquiano, Juan Pedro Caraça-Valente HernándeziD, Alejandro Rodríguez‐GonzáleziD
Abstract
BackgroundDrug repurposing plays a significant role in bringing effective treatments for certain diseases faster and more cost-effectively. Successful repurposing cases are mostly supported by a classical paradigm that stems from de novo drug development. This paradigm is based on the "one-drug-one-target-one-disease" idea. It consists of designing drugs specifically for a single disease and its drugs gene target. In this article, we investigated the use of biological pathways as potential elements to achieve effective drug repurposing. MethodsConsidering a total of 4.214 successful cases of drug repurposing, we identified cases in which biological pathways serve as the underlying basis for successful repurposing, referred to as DREBIOP. Once the repurposing cases based on pathways were identified, we studied the inherent patterns within them by considering the different biological elements associated with this dataset, as well as the pathways involved in these cases. Furthermore, we obtained gene-disease association values to demonstrate the diminished significance of the drugs gene target in these repurposing cases. To achieve this, we compared the values obtained for the DREBIOP set with the overall association values found in DISNET, as well as with the drugs target gene (DREGE) based repurposing cases using the Mann-Whitney U Test. ResultsA collection of drug repurposing cases, known as DREBIOP, was identified as a result. DREBIOP cases exhibit distinct characteristics when compared to DREGE cases. Notably, DREBIOP cases are associated with a higher number of biological pathways, with Vitamin D Metabolism and ACE inhibitor being the most prominent pathways involved. Additionally, it was observed that the association values of GDAs in DREBIOP cases are significantly lower than those in DREGE cases (p-value View larger version (20K): org.highwire.dtl.DTLVardef@187d2ceorg.highwire.dtl.DTLVardef@210b96org.highwire.dtl.DTLVardef@17fc4b7org.highwire.dtl.DTLVardef@14c0184_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 15
- FWCI
- 3.17
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Prioritization of Potential Drugs Through Pathway-Based Drug Repurposing and Network Proximity Analysis
Belén Otero-Carrasco, Lucia Prieto Santamaría, Alejandro Rodríguez‐González·Proceedings - IEEE Symposium on Computer-Based Medical SystemsPeer-reviewed·Jun 18, 2025
- The Drug Repurposing Encyclopedia (DRE): a web server for systematic drug repurposing across 20 organisms
Xuexin Li, Lu Pan, … Óscar Fernández-Capetillo·bioRxiv·Mar 10, 2023
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies
Susanna Savander, Nurettin Nusret Curabaz, … Ziaurrehman Tanoli·Briefings in BioinformaticsPeer-reviewed·Nov 1, 2025
- DReAmocracy: A Method to Capitalize on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing
Kyriaki Savva, Margarita Zachariou, … George M. Spyrou·International Journal of Molecular SciencesPeer-reviewed·May 13, 2024
- Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs.
Daniele Parisi, Melissa F. Adasme, … Michael Schroeder·Computational and Structural Biotechnology JournalPeer-reviewed·Jan 1, 2020
- Systematic AI-Driven Drug Repurposing via Clinical Trial Data Mining: A Framework and Six Cross-Therapeutic Case Studies.
Vrinda Gote·bioRxiv·Jun 14, 2026